Oct. 22 at 11:41 PM
$UNCY I have a sizeable allocation in the stock and continue to hold because I believe they have a real shot at a win here.
That said, this company is a case study in how not to run a public company. Communication is key and unfortunately, they’ve failed investors on multiple occasions.
A simple update could go a long way in maintaining confidence. Something along the lines of:
“We submitted the request for a Type A meeting on [xx/xx/xxxx] and are awaiting a response. Due to [reason], the response has been delayed, but we will provide an update as soon as we receive [next step].”
Whoever is advising them on PR is doing a poor job, and the CEO has been a disappointment. Gupta needs to move past the “why this drug is important” to actually making sh* happen.
I hope someone at the company takes note of this.
